Melbourne, Aug 15, 2007 AEST (ABN Newswire) - Melbourne based Biotech Solagran Limited (ASX: SLA) today announced that arrangements were being put in place in St Petersburg to supply patients outside Russia with its liver disease drug Ropren, consistent with international regulatory guidelines.
Since the full results of the Ropren liver disease clinical trials were presented to an audience of 2,500 clinicians and researchers at an international gastroenterology conference in St Petersburg in May, and particularly since Ropren received final regulatory approval from the Russian Ministry of Health in July, Solagran and its manufacturing partner in St Petersburg have received a steady stream of enquiries regarding the availability of Ropren for patients with cirrhosis and other serious liver diseases living in the UK, Western Europe, Scandinavia, North America and Asia. There have also been many enquiries from doctors in the former Soviet Republics (CIS countries).
In response to these requests, Solagran's manufacturing partner has taken the decision to put in place the necessary administrative procedures to enable them to provide Ropren to patients outside Russia, consistent with the specific "compassionate use" and "personal supply" provisions that exist within the regulatory frameworks of each country.
Solagran has agreed to a price in the range 3,500 to 6,000 US Dollars per three month course, after independent confirmation that such a price would compare favourably with that of other therapies currently used to treat serious liver diseases.
Solagran also announced that the pricing of Ropren in Russia will be resolved with the Russian Ministry of Health in conjunction with the granting of its manufacturing licence. This is expected to occur at the latest in November.
Contact
Denis Kilroy
Executive Director
Solagran Limited
TEL: +61 3 9820 2699
MOB: +61 411 222 844 (m)
www.solagran.com
| ||
|
